•Pateras IS, Kotsakis A, Avgeris M, Baliou E, Kouroupakis P, Patsea E, et al. Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in "Immune Desert" NSCLC. Cancers (Basel). 2021;13(7).

•Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, et al. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomi

•Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, et al. A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment ration

•Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, et al. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol Immunother. 2012;61(2):157-68.

•Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K. Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Ann Transl Med. 2016;4(14):266.

•June 1st, 2017 : Kriptic announces results of its Phase IIb lung cancer trial of Vx-001, a therapeutic vaccine based on optimized cryptic peptides.

•June 20, 2016 : Kriptic publishes article supporting potential of proprietary optimized cryptic peptides as ‘universal neoantigens

•March 16, 2016 : Kriptic completes enrollment of phase 2b lung cancer trial of first therapeutic vaccine based on optimized cryptic peptides

•June 22, 2015 : Kriptic granted Japanese patent for new cancer vaccine candidates.

•March 30 2015 : Kriptic appoints founder and chief scientific officer, Dr. Kostas Kosmatopoulos, as CEO.

•December 1st, 2014 : Kriptic announces the inclusion of the 110th patients in the phase IIb clinical study with the Vx-001 vaccine in NSCLC.

•September 1st, 2012 :Kriptic announces that the first patient has been randomized in the multicenter Phase IIb trial (Vx-001-201) for the treatment of non-small-cell lung cancer with the therapeutic cancer vaccine Vx-001.

•February 28th, 2012 : Kriptic announces that two patent applications covering Vx-001 and Vx-006 vaccines have been granted in China and Japan respectively.

•August 30th, 2011 : Kriptic announces publication of two articles in Cancer Immunology Immunotherapy and in Annals of Oncology presenting immunological and clinical data in cancer patients vaccinated with Vx-001.

•20/02/09 : Kriptic’s lead product, Vx-001, has been granted orphan drug status by FDA for the treatment of NSCLC for HLA-A2+ patients with TERT+ tumours.

•30/05/08 : Kriptic to Present Latest Clinical and Immunological Data of its Vx-001 Cancer Vaccine at the ASCO 2008 Annual Meeting.

•11/04/08 : Kriptic to Present Latest Clinical and Immunological Data of its Vx-001 Cancer Vaccine at the 99th AACR Annual Meeting.

•16/11/07 : Kriptic Receives from EMA an European Orphan Medicinal Product Designation for Vx-001.

•02/07/07 : Kriptic publishes encouraging results in the Journal of Clinical Oncology for the treatment of Non-Small Cell Lung Cancer with Vx-001.

•03/06/07 : Kriptic Presents Preliminary Results from Vx-001 Vaccine Clinical Trial on Lung Cancer at the ASCO 2007 annual meeting.

•03/04/06 : Kriptic and Institut Pasteur Announce Collaboration to Develop New Products and Models for Cancer Immunotherapy.

•14/03/06 : Kriptic to Present Latest Clinical Data of its Vx-001 Cancer Vaccine at the 97thAACR Annual Meeting.